{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:22:12Z","timestamp":1787948532597,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40273-026-01621-4","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:26:31Z","timestamp":1780395991000},"page":"1077-1092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cost-Effectiveness and Budget-Impact Analysis of Semaglutide in Heart Failure with Preserved Ejection Fraction and Obesity in the German Health-Care System"],"prefix":"10.1007","volume":"44","author":[{"given":"Bent","family":"Estler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Fr\u00f6hlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"T\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Frankenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"1621_CR1","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42:3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"key":"1621_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101025","volume":"3","author":"WS Weintraub","year":"2024","unstructured":"Weintraub WS, Alva M. The societal burden of heart failure with preserved or mid-range ejection fraction. JACC Adv. 2024;3:101025. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101025.","journal-title":"JACC Adv"},{"key":"1621_CR3","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1161\/circheartfailure.113.000359","volume":"6","author":"SM Joseph","year":"2013","unstructured":"Joseph SM, Novak E, Arnold SV, Jones PG, Khattak H, Platts AE, et al. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail. 2013;6:1139\u201346. https:\/\/doi.org\/10.1161\/circheartfailure.113.000359.","journal-title":"Circ Heart Fail"},{"key":"1621_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jchf.2022.03.003","volume":"10","author":"J Butler","year":"2022","unstructured":"Butler J, Shahzeb Khan M, Lindenfeld J, Abraham WT, Savarese G, Salsali A, et al. Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF. JACC Heart Fail. 2022;10:651\u201361. https:\/\/doi.org\/10.1016\/j.jchf.2022.03.003.","journal-title":"JACC Heart Fail"},{"key":"1621_CR5","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","volume":"118","author":"BA Borlaug","year":"2023","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023;118:3434\u201350. https:\/\/doi.org\/10.1093\/cvr\/cvac120.","journal-title":"Cardiovasc Res"},{"key":"1621_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/ehf2.14560","volume":"11","author":"G Cimino","year":"2024","unstructured":"Cimino G, Vaduganathan M, Lombardi CM, Pagnesi M, Vizzardi E, Tomasoni D, et al. Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists. ESC Heart Fail. 2024;11:649\u201361. https:\/\/doi.org\/10.1002\/ehf2.14560.","journal-title":"ESC Heart Fail"},{"key":"1621_CR7","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10741-024-10439-1","volume":"30","author":"A Vacca","year":"2025","unstructured":"Vacca A, Wang R, Nambiar N, Capone F, Farrelly C, Mostafa A, et al. Lifestyle interventions in cardiometabolic HFpEF: dietary and exercise modalities. Heart Fail Rev. 2025;30:637\u201355. https:\/\/doi.org\/10.1007\/s10741-024-10439-1.","journal-title":"Heart Fail Rev"},{"key":"1621_CR8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Gaal LFV, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183.","journal-title":"N Engl J Med"},{"key":"1621_CR9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2306963.","journal-title":"N Engl J Med"},{"key":"1621_CR10","unstructured":"IQWiG. Allgemeine Methoden (General Methods). Version 7.0. https:\/\/www.iqwig.de\/methoden\/allgemeine-methoden_version-7-0.pdf: 2023."},{"key":"1621_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, Jaime Caro J, Lee KM, Minchin M, et al. Budget impact analysis\u2014principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17:5\u201314. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291.","journal-title":"Value Health"},{"key":"1621_CR12","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jamainternmed.2022.5010","volume":"182","author":"J Zheng","year":"2022","unstructured":"Zheng J, Parizo JT, Spertus JA, Heidenreich PA, Sandhu AT. Cost-effectiveness of empagliflozin in patients with heart failure with preserved ejection fraction. JAMA Intern Med. 2022;182:1278\u201388. https:\/\/doi.org\/10.1001\/jamainternmed.2022.5010.","journal-title":"JAMA Intern Med"},{"key":"1621_CR13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029042","volume":"13","author":"OS Reifsnider","year":"2024","unstructured":"Reifsnider OS, Tafazzoli A, Linden S, Ishak J, Rakonczai P, Stargardter M, et al. Cost\u2010effectiveness analysis of empagliflozin for treatment of patients with heart failure with reduced ejection fraction in the United States. J Am Heart Assoc. 2024;13:e029042. https:\/\/doi.org\/10.1161\/JAHA.123.029042.","journal-title":"J Am Heart Assoc"},{"key":"1621_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jchf.2015.10.015","volume":"4","author":"AA Kelkar","year":"2016","unstructured":"Kelkar AA, Spertus J, Pang P, Pierson RF, Cody RJ, Pina IL, et al. Utility of patient-reported outcome instruments in heart failure. JACC Heart Fail. 2016;4:165\u201375. https:\/\/doi.org\/10.1016\/j.jchf.2015.10.015.","journal-title":"JACC Heart Fail"},{"key":"1621_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1161\/circulationaha.123.067505","volume":"149","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Verma S, Borlaug BA, Butler J, Davies MJ, Jensen JT, et al. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024;149:204\u201316. https:\/\/doi.org\/10.1161\/circulationaha.123.067505.","journal-title":"Circulation"},{"key":"1621_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpopen.2021.100063","volume":"3","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Health Policy Open. 2022;3:100063. https:\/\/doi.org\/10.1016\/j.hpopen.2021.100063.","journal-title":"Health Policy Open"},{"key":"1621_CR17","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","volume":"30","author":"DH Ryan","year":"2024","unstructured":"Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30:2049\u201357. https:\/\/doi.org\/10.1038\/s41591-024-02996-7.","journal-title":"Nat Med"},{"key":"1621_CR18","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/ehf2.12606","volume":"7","author":"D Hashemi","year":"2020","unstructured":"Hashemi D, Dettmann L, Trippel TD, Holzendorf V, Petutschnigg J, Wachter R, et al. Economic impact of heart failure with preserved ejection fraction: insights from the ALDO-DHF trial. ESC Heart Fail. 2020;7:786\u201393. https:\/\/doi.org\/10.1002\/ehf2.12606.","journal-title":"ESC Heart Fail."},{"key":"1621_CR19","unstructured":"(InEK) IfdEiK. aG-DRG-Fallpauschalen-Katalog 2025 nebst Anlagen. In; 2025."},{"key":"1621_CR20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11136-007-9302-5","volume":"17","author":"JA Spertus","year":"2008","unstructured":"Spertus JA, Jones PG, Kim J, Globe D. Validity, reliability, and responsiveness of the Kansas City Cardiomyopathy Questionnaire in anemic heart failure patients. Qual Life Res. 2008;17:291\u20138. https:\/\/doi.org\/10.1007\/s11136-007-9302-5.","journal-title":"Qual Life Res"},{"key":"1621_CR21","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/ehjqcco\/qcab014","volume":"7","author":"M Thomas","year":"2021","unstructured":"Thomas M, Jones PG, Cohen DJ, Suzanne AV, Magnuson EA, Wang K, et al. Predicting the EQ-5D utilities from the Kansas City Cardiomyopathy Questionnaire in patients with heart failure. Eur Heart J Qual Care Clin Outcomes. 2021;7:388\u201396. https:\/\/doi.org\/10.1093\/ehjqcco\/qcab014.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"1621_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","volume":"36","author":"K Ludwig","year":"2018","unstructured":"Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the EQ-5D-5L. Pharmacoeconomics. 2018;36:663\u201374. https:\/\/doi.org\/10.1007\/s40273-018-0615-8.","journal-title":"Pharmacoeconomics"},{"key":"1621_CR23","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jval.2024.03.013","volume":"27","author":"S Ghabri","year":"2024","unstructured":"Ghabri S, Dawoud D, Drummond M. Methods for including adverse events in economic evaluations: suggestions for improvement. Value Health. 2024;27:936\u201342. https:\/\/doi.org\/10.1016\/j.jval.2024.03.013.","journal-title":"Value Health"},{"key":"1621_CR24","unstructured":"(Destatis) SB. Germany\u2019s population at 82.7 million on 15 May 2022 \u2013 Results of the 2022 Census. https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/_inhalt.html. 2024. Accessed 29.11.2025."},{"key":"1621_CR25","unstructured":"J H, MK A, A S, J B. Prevalence of heart failure in Germany \u2013 Nationwide trends, regional variation, and frequent comorbidities. In: Versorgungsatlas-Report. Berlin: Central Research Institute for Ambulatory Health Care in Germany (Zi); 2018."},{"key":"1621_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005652","volume":"12","author":"J Lup\u00f3n","year":"2019","unstructured":"Lup\u00f3n J, Gavidia-Bovadilla G, Ferrer E, de Antonio M, Perera-Lluna A, L\u00f3pez-Ayerbe J, et al. Heart failure with preserved ejection fraction infrequently evolves toward a reduced phenotype in long-term survivors. Circ Heart Fail. 2019;12:e005652. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005652.","journal-title":"Circ Heart Fail"},{"key":"1621_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/jama.2023.2020","volume":"329","author":"MM Redfield","year":"2023","unstructured":"Redfield MM, Borlaug BA. Heart failure with preserved ejection fraction: a review. JAMA. 2023;329:827\u201338. https:\/\/doi.org\/10.1001\/jama.2023.2020.","journal-title":"JAMA"},{"key":"1621_CR28","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40258-023-00803-x","volume":"21","author":"A Gandjour","year":"2023","unstructured":"Gandjour A. A model-based estimate of the cost-effectiveness threshold in Germany. Appl Health Econ Health Policy. 2023;21:627\u201335. https:\/\/doi.org\/10.1007\/s40258-023-00803-x.","journal-title":"Appl Health Econ Health Policy"},{"key":"1621_CR29","unstructured":"(Destatis) SB. Health expenditure. Statistisches Bundesamt (Destatis). https:\/\/www.destatis.de\/EN\/Themes\/Society-Environment\/Health\/Health-Expenditure\/_node.html. 2025. Accessed 1 December 2025."},{"key":"1621_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ejhf.3197","volume":"26","author":"JA Davis","year":"2024","unstructured":"Davis JA, Booth D, McEwan P, Solomon SD, McMurray JJV, de Boer RA, et al. Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: a pooled analysis of DAPA-HF and DELIVER data. Eur J Heart Fail. 2024;26:664\u201373. https:\/\/doi.org\/10.1002\/ejhf.3197.","journal-title":"Eur J Heart Fail"},{"key":"1621_CR31","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s40258-023-00815-7","volume":"21","author":"M B\u00fcssgen","year":"2023","unstructured":"B\u00fcssgen M, Stargardt T. 10 years of AMNOG: what is the willingness-to-pay for pharmaceuticals in Germany? Appl Health Econ Health Policy. 2023;21:751\u20139. https:\/\/doi.org\/10.1007\/s40258-023-00815-7.","journal-title":"Appl Health Econ Health Policy"},{"key":"1621_CR32","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1093\/eurheartj\/ehaf323","volume":"46","author":"M Darvish","year":"2025","unstructured":"Darvish M, Shakoor A, Feyz L, Schaap J, van Mieghem NM, de Boer RA, et al. Heart failure: assessment of the global economic burden. Eur Heart J. 2025;46:3069\u201378. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf323.","journal-title":"Eur Heart J"},{"key":"1621_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078242","volume":"385","author":"N Simms-Williams","year":"2024","unstructured":"Simms-Williams N, Treves N, Yin H, Lu S, Yu O, Pradhan R, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024;385:e078242. https:\/\/doi.org\/10.1136\/bmj-2023-078242.","journal-title":"BMJ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01621-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01621-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01621-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:41:01Z","timestamp":1787380861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01621-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01621-4","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NF reports \u201cpayment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events\u201d. No other conflict of interest declared.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}